Actos, Glustin (pioglitazone) is a small molecule pharmaceutical. Pioglitazone was first approved as Actos on 1999-07-15. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against peroxisome proliferator-activated receptor gamma. In addition, it is known to target transient receptor potential cation channel subfamily M member 3.
|Trade Name||Actos, Glustin|
|Indication||type 2 diabetes mellitus|
|Drug Class||Ppst agonists (thiazolidene derivatives)|